tislelizumab
tislelizumab: 60 clinical trials tracked.
tislelizumab evidence translation
What we can confirm
60 tracked trials
What it means
What to watch
Prepared research question
What is verified about tislelizumab, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 11 study sponsors
Related indications
Clinical Trials (60)showing 10 most recent
Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden
Primary endpoint: Progression-free survival
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-85738, Alone or in Combination With Other Antitumor Agents, in Patients With Advanced or Metastatic Solid Tumors With RAS Mutations
Primary endpoint: Phase 1a (Part A and Part B): Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
A Phase 2 Study of Tislelizumab Administered With Alternative Dosing Schedules Plus Chemotherapy as First-line Treatment in Japanese Patients With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Primary endpoint: Serum Concentrations of Tislelizumab at Specified Time Points
A Prospective, Single-arm, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With Tislelizumab and Platinum-based Doublet Chemotherapy as Induction/Conversion Therapy for Potentially Resectable Stage III Non-small Cell Lung Cancer With Bulky Disease.
Primary endpoint: Major Pathological Response (MPR) Rate
A Phase II, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
Primary endpoint: Objective Response Rate (ORR)
AACR Adaptive Biomarker-Driven Organ Preservation Trial In Gastroesophageal Adenocarcinomas (AACR-ADOPT-GEA)
Primary endpoint: Pathological Complete Response (pathCR) Rate (Stage I).
A Phase II Study Evaluating the Efficacy and Safety of SKB315 Combination Therapy in Claudin18.2 Positive Patients With Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Primary endpoint: Objective Response Rate (ORR)
A Pilot Study of Neoadjuvant mFOLFIRINOX and ELI002-7P Treatment With or Without Tislelizumab in Borderline and Resectable Pancreatic Ductal Adenocarcinoma
Primary endpoint: the proportion of patients with a Grade 3 or higher drug-related adverse event (AE)
KontRASt-R: An Open-label, Multi-center, Rollover Study for Participants Who Have Been Previously Enrolled Into a Novartis-sponsored Opnurasib (JDQ443) Study and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
Primary endpoint: Number of participants receiving opnurasib as single agent or in combination with other study treatments
A Real-World Evaluation of Tislelizumab Treatment Patterns and Effectiveness in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer and Small Cell Lung Cancer
Primary endpoint: Time from Diagnosis to First Dose